Prevalence and Pattern of KRAS and NRAS Mutations in Colorectal Cancer: A Libyan Retrospective Study
International Research Journal of Oncology,
About 53% of colorectal cancer (CRC) patients were reported to have the Kirsten rat sarcoma viral oncogene homolog (KRAS) gene mutations. These mutations in the KRAS gene are able to render the targeted therapy agents such as monoclonal antibodies cetuximab and panitumumab ineffective against the epidermal growth factor receptor (EGFR). Disparities between regions have been described in the literature regarding these mutations. This is an original investigation aimed at characterising the frequency and patterns of KRAS mutations in Libyan patients with colorectal cancer. Tissue samples of 79 cases of colorectal cancer were analysed for KRAS and NRAS mutations. Of these, 44 (55.7%) reported positive. In the KRAS positive patients, there were 23 (52.3%) males and 21 (47.7%) females. Majority of cases (77.0%) were with point mutations in codon 12 whereas (7%) had a single mutation in codon 13. There were 3 patients showing mutation in codon 61 with two nucleotide changes whereas the last 4 patients exhibited three nucleotide changes in codon 146. The more prevalent KRAS mutation was p.Gly12Val (c.35G>T) (29.5%), followed by p.Gly12Asp (c.35G>A) (25%). The G>A transitions in both codons 12 and 13 accounted for 41.0% of all the mutant KRAS cases. The transversions G>T in codon 12 alone forms 38.6% of the total KRAS mutation. The p.Gly12Val (c.35G>T) mutation had the highest frequency in both males (26.1%) and females (33.3%). Same tendency also was seen in p.Gly12Asp (c.35G>A) mutation but to lesser extent with (30.4%) in male and (19%) in female. Interestingly, the p.Gly13Asp (c.38G>A) mutation had pure appearance in male. Multiple mutations in the same individual were detected in 7 patients in this cohort (16%). Our results showed a relatively higher prevalence of KRAS mutation in Libyan patients compared to other analogous data observed worldwide. Two samples only out of 29 showed mutation in NRAS codon 61. Being a retrospective study with small sample size were the main limitations for this study. Thus we recommend that conduction of larger studies is needed in the future.
- colorectal cancer (CRC)
- Libyan patients
How to Cite
Sirisena ND, et al. The pattern of KRAS mutations in metastatic colorectal cancer: a retrospective audit from Sri Lanka. BMC research notes. 2017;10(1):392-392.
Inoue Y, et al. The prognostic value of KRAS mutations in patients with colorectal cancer. Oncol Rep. 2012;28(5):1579-84.
Tan C, Du X. KRAS mutation testing in metastatic colorectal cancer. World Journal of Gastroenterology. 2012;18(37):5171-5180.
Maughan TS, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet. 2011;377(9783):2103-14.
Wang J, et al. Direct sequencing is a reliable assay with good clinical applicability for KRAS mutation testing in colorectal cancer. Cancer Biomark. 2013;13(2):89-97.
Amicarelli G, et al. FLAG assay as a novel method for real-time signal generation during PCR: application to detection and genotyping of KRAS codon 12 mutations. Nucleic Acids Res. 2007; 35(19): e131.
Harlé A, et al. Rare RAS mutations in metastatic colorectal cancer detected during routine ras genotyping using next generation sequencing. Target Oncol. 2016;11(3):363-70.
Yamane L, et al. Serrated pathway in colorectal carcinogenesis. World Journal of Gastroenterology. 2014;20(10):2634-2640.
Behl AS, et al. Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer. Journal of the National Cancer Institute. 2012;104(23):1785-1795.
Veldore VH, et al. Prevalence of KRAS mutations in metastatic colorectal cancer: A retrospective observational study from India. Indian J Cancer. 2014;51(4):531-7.
De Roock W, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753-62.
Allegra CJ, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27(12):2091-6.
Van Cutsem E, Oliveira J. Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(Suppl 4):61-3.
Lièvre A, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66(8):3992-5.
Coppedè F, et al. Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer. World Journal of Gastroenterology. 2014;20(4):943-956.
Li L, Ma BB. Colorectal cancer in Chinese patients: current and emerging treatment options. OncoTargets and therapy. 2014;7: 1817-1828.
De Roock W, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. Jama. 2010; 304(16):1812-20.
Solassol J, et al. Multi-center evaluation of the fully automated pcr-based idylla™ kras mutation assay for rapid kras mutation status determination on formalin-fixed paraffin-embedded tissue of human colorectal cancer. PLoS One. 2016;11(9):e0163444.
Gil Ferreira C, et al. KRAS mutations: variable incidences in a Brazilian cohort of 8,234 metastatic colorectal cancer patients. BMC Gastroenterol. 2014;14: 73.
Tougeron D, et al. Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol. 2013;24(5):1267-73.
Atreya CE, Corcoran RB, Kopetz S. Expanded RAS: refining the patient population. J Clin Oncol. 2015;33(7): 682-5.
Hecht JR, et al. Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. Cancer Treat Rev. 2015;41(8):653-9.
Sorich MJ, et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol. 2015;26(1):13-21.
Aissi S, et al. KRAS mutations in colorectal cancer from Tunisia: relationships with clinicopathologic variables and data on TP53 mutations and microsatellite instability. Mol Biol Rep. 2013;40(11):6107-12.
Elbjeirami, W.M. and M.A. Sughayer, KRAS mutations and subtyping in colorectal cancer in Jordanian patients. Oncol Lett. 2012;4(4):705-710.
Hurtado C, et al. KRAS gene somatic mutations in Chilean patients with colorectal cancer. Rev Med Chil. 2014;142 (11):1407-14.
Jakovljevic K, et al. KRAS and BRAF mutations in Serbian patients with colorectal cancer. J buon. 2012;17(3):575-80.
Marchoudi N, et al. Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer. Pathol Biol (Paris). 2013;61(6):273-6.
Mazurenko NN, et al. The frequency and spectrum of KRAS mutations in metastatic colorectal cancer. Vopr Onkol. 2013;59(6) :751-5.
Nakanishi R, et al. Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer. International Journal of Clinical Oncology. 2013;18(6):1042-1048.
Abstract View: 89 times
PDF Download: 48 times